Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | January 15, 2026 | January 16, 2026 |
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director | June 15, 2026 | June 17, 2026 |
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
| Transcode Therapeutics, Inc.RNAZ · Entity 8499 | Director | June 14, 2024 | June 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date January 15, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,930 |
Ending reported balance
After 2026-01-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-15 · Exercise / conversion · Acquired 11,000 · Balance 20,930 Row 2 · 2026-01-15 · Sale · Disposed 9,290 · Balance 11,640 F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-01-15 · Sale · Disposed 1,710 · Balance 9,930 F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.11 · Expires 2031-01-17 | Direct | 0 |
Reported balance
After 2026-01-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-15 · Exercise / conversion · Disposed 11,000 · Balance 0 F3: The stock option is fully vested. F4: In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The stock option is fully vested.
F4: In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,500 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,500 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
First Tracks Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,960 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Exercise / conversion · Acquired 6,030 · Balance 15,960 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Exercise / conversion · Disposed 6,030 · Balance 0 F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock award ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2: The RSUs vests as to 100% of the total RSUs on June 15, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,342 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 52,342 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | Indirectby ALMA Life Sciences, LLC | 20,000 |
Reported balance
Holding disclosure · report date 2026-05-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F2: The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The Reporting Person is the Co-Founder and Co-Chief Executive Officer of Alma Life Sciences, LLC and may be deemed to beneficially own the securities held by Alma Life Sciences, LLC. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Alma Life Sciences, LLC, except to the extent of her pecuniary interest therein.
F3: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Transcode Therapeutics, Inc.
Report date June 14, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.20 · Expires 2034-06-13 | Direct | 70,000 |
Reported balance
After 2024-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-14 · Grant · Acquired 70,000 · Balance 70,000 F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fifty percent (50%) of the shares subject to this option vested and became exercisable on January 1, 2024, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pfenex Inc.
Report date October 01, 2020 · Filed October 05, 2020
Section 16 reporting ended · disclosed 2020-10-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49 · Expires 2029-02-28 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-10-01 · Other · Disposed 25,000 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.43 · Expires 2030-05-08 | Direct | 0 |
Reported balance
After 2020-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-01 · Other · Disposed 18,000 · Balance 0 F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. F2: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings.
F2: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2023 Filed Jan 11, 2023 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001209191-23-002882 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 Underlying: Common Stock · 10,600 shares Expires 2033-01-05 F1 · derivative.exercise_date: The stock option vests as to 1/12 of the total shares monthly commencing on February 6, 2023 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 22:02 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 2,222 | $18.00 | $39,996.00 |
DisclosureSEC source: 0001193805-22-001748 · e618133_4-marquet.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Via Alma Life Sciences, LLC Disclosed balance after: 24,942 Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 10:10 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 16,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-22-019512 · ownership.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 16,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: Options vest monthly over 12 months from date of grant. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:16 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001193805-22-001023 · e621784_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 00:25 UTC | Transcode Therapeutics, Inc. RNAZ · Entity 8499 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001104659-22-073635 · tm2219203-2_4seq1.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001209191-22-009361 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2022 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:32 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001193805-21-000928 · e620748_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| February 10, 2021 Filed Feb 13, 2021 02:40 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $29.70 | $0.00 |
DisclosureSEC source: 0001209191-21-010531 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: The stock option vests as of 1/12 of the total shares monthly beginning on March 10, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 18, 2021 Filed Jan 19, 2021 21:36 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 784 | $0.00 Strike: $26.11 | $0.00 |
DisclosureSEC source: 0001209191-21-004027 · doc4.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784 Underlying: Common Stock · 784 shares Expires 2031-01-17 F2 · derivative.exercise_date: The stock option shall be fully vested as of February 12, 2021, subject to the Reporting Person's continued service on the vesting date. Read SEC document |
| January 18, 2021 Filed Jan 19, 2021 21:36 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $26.11 | $0.00 |
DisclosureSEC source: 0001209191-21-004027 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-01-17 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning on February 18, 2021 until fully vested, subject to the Reporting Person's continued service on each vesting date. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:36 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $6.43 | Not disclosed |
DisclosureSEC source: 0000899243-20-027425 · doc4.xml · derivative · entry 2 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2030-05-08 F1 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan). Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:36 UTC | Pfenex Inc. PFNX · Entity 146052 | OtherStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $4.49 | Not disclosed |
DisclosureSEC source: 0000899243-20-027425 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2029-02-28 F1 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, each option with an exercise price equal to or less than the Cash Portion that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested, will be cancelled and converted into a right to receive, with respect to each share of Issuer Common stock subject to such option, an amount in cash, without interest, equal to the excess, if any, of (i) the Cash Portion over the per share exercise price of such option, plus (ii) the CVR Portion (the "Option Consideration"). All Option Consideration will be paid without interest and less any applicable tax withholdings. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $40.70 | $0.00 |
DisclosureSEC source: 0001193805-20-000745 · e619724_4-marquet.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| May 08, 2020 Filed May 11, 2020 20:11 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $6.43 | $0.00 |
DisclosureSEC source: 0000899243-20-012692 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-05-08 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after May 8, 2020, subject to the reporting person's continuing service through the date of the Annual Meeting. Notwithstanding the foregoing, one hundred percent (100%) of the shares subject to the option shall vest and become exercisable as of immediately prior to a Change in Control (as such term is defined in the Issuer's 2014 Equity Incentive Plan). Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:12 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026116 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-24 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| September 13, 2019 Filed Sep 18, 2019 01:37 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | PurchaseCommon Stock | 2,300 | $10.58 | $24,334.00 |
DisclosureSEC source: 0000899243-19-023769 · doc4.xml · nonDerivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Via Alma Life Sciences, LLC Disclosed balance after: 22,720 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 19:37 UTC | Pfenex Inc. PFNX · Entity 146052 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0000899243-19-005932 · doc4.xml · derivative · entry 1 Marquet Magda · CIK 0001631486 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the option shall vest and become exercisable on the date of the next annual meeting of the Issuer's stockholders (the "Annual Meeting") held after February 28, 2019, subject to the reporting person's continuing service through the date of the Annual Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.